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CD44v9 is expressed in cancer stem cells (CSC) and stabilizes the glutamate‐cystine
transporter xCT on the cytoplasmic membrane, thereby decreasing intracellular
levels of reactive oxygen species (ROS). This mechanism confers ROS resistance to
CSC and CD44v9‐expressing cancer cells. The aims of the present study were to
assess: (i) expression status of CD44v9 and xCT in hepatocellular carcinoma (HCC)
tissues, including those derived from patients treated with hepatic arterial infusion
chemoembolization (HAIC) therapy with cisplatin (CDDP); and (ii) whether combina-
tion of CDDP with sulfasalazine (SASP), an inhibitor of xCT, was more effective on
tumor cells than CDDP alone by inducing ROS‐mediated apoptosis. Twenty non‐pre-
treated HCC tissues and 7 HCC tissues administered HAIC therapy with CDDP
before surgical resection were subjected to immunohistochemistry analysis of
CD44v9 and xCT expression. Human HCC cell lines HAK‐1A and HAK‐1B were
used in this study; the latter was also used for xenograft experiments in nude mice
to assess in vivo efficacy of combination treatment. CD44v9 positivity was signifi-
cantly higher in HAIC‐treated tissues (5/7) than in non‐pretreated tissues (2/30), sug-
gesting the involvement of CD44v9 in the resistance to HAIC. xCT was significantly
expressed in poorly differentiated HCC tissues. Combination treatment effectively
killed the CD44v9‐harboring HAK‐1B cells through ROS‐mediated apoptosis and sig-
nificantly decreased xenografted tumor growth. In conclusion, the xCT inhibitor
SASP augmented ROS‐mediated apoptosis in CDDP‐treated HCC cells, in which the
CD44v9‐xCT system functioned. As CD44v9 is typically expressed in HAIC‐resistant
HCC cells, combination treatment with SASP with CDDP may overcome such drug
resistance.
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1 | INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most frequent cancer
worldwide with over 740 000 new cases per year and the third
leading cause of cancer‐related deaths, with a growing incidence
in recent years.1 Despite early diagnosis of small HCC, it remains
difficult to treat advanced‐stage disease because of its high poten-
tial of intra‐ and extrahepatic multiple metastases and refractori-
ness to chemotherapeutic treatments, including transcatheter
arterial chemoembolization (TACE),2 hepatic arterial infusion
chemoembolization (HAIC),3 and the molecular‐targeted drug sora-
fenib.4 To overcome limitations in therapeutic efficacy, novel drugs
targeting tumor refractoriness are needed. Refractoriness to
chemotherapeutic treatments is attributable to the unique biologi-
cal features of cancer stem cells (CSC) or CSC‐like cells.5 These
cells consist of a small population of cancer cells that are capable
of self‐renewal and tumor initiation.6 Therefore, targeting CSC or
CSC‐like cells is a key strategy for improving the outcomes of
cancer patients. In HCC, markers for CSC are thought to include
CD13,7 CD44,8 CD90,9 CD133,10 EpCAM,11 and aldehyde dehy-
drogenase,12 but no agents specifically targeting CSC have been
developed.
CD44 is a transmembrane protein and functions as a cellular
adhesion molecule for hyaluronic acid, a major component of the
extracellular matrix. This molecule plays important roles in various
physiological and pathological processes, including tumor cell prolif-
eration, invasion, and metastasis.13 It has also been identified as a
cell surface marker for CSC of solid tumors. Of the several splice
variant isoforms of CD44, variant 9 (v9) was recently found in
CSC,14 where it binds to xCT, a subunit of a cystine‐glutamate anti-
porter known as system xc(–). Such binding stabilizes expression of
this transporter system at the cell surface and thereby promotes
intracellular synthesis of the antioxidant glutathione (GSH) from
incorporated cysteine.15 Thus, expression of CD44v9 in tumor cells
confers resistance to oxidative stress and promotes tumor growth
and resistance to treatments.
Salazosulfapyridine (SASP), a well‐known agent used to treat
ulcerative colitis and rheumatoid arthritis, is a specific inhibitor of
xCT‐mediated cystine transport and suppresses the proliferation of
CD44v‐positive cancer cells.16 In animal models, ablation of this sys-
tem suppressed cancer growth and in patients with advanced gastric
cancer, SASP reduced the CD44v‐positive cancer cell population and
decreased intratumoral GSH levels.17 These findings suggest that
SASP is a safe and potential therapeutic agent targeting CD44v‐
expressing stem cell‐like cancer cells in the clinical setting.
In HCC, the effect of CD44 and its isoforms on tumor aggres-
siveness and prognosis of patients is unclear. Recently, high expres-
sion levels of CD44v9 were observed as a potential biomarker of
poor prognosis in patients with HCC.18 However, the expression sta-
tus of both CD44v9 and xCT in resistant HCC cells to chemothera-
peutic treatment has not been investigated. In the present study, we
observed higher expression of the CD44v9/xCT system in surviving
HCC cells after HAIC therapy than in those unexposed to
chemotherapeutic agents prior to surgical resection. These findings
provide mechanistic insights into how SASP targets the system and
induces reactive oxygen species (ROS)‐mediated apoptosis in HCC
cells.
2 | MATERIALS AND METHODS
2.1 | Patients and tumor tissues
Thirty‐seven patients (28 males and 9 females) with HCC were
enrolled in this study (Table 1). They underwent curative hepatec-
tomy between 2000 and 2015 at Kurume University Hospital. Mean
age of the patients was 71 years (range, 53‐84 years). Three patients
were positive for hepatitis B surface antigen, and 26 were positive
for anti‐hepatitis C virus antibody. HCC tissues consisted of 30 pri-
marily resected tissues and 7 pretreated by HAIC therapy with a
combination of lipiodol‐suspended cisplatin (CDDP) and continuous
infusion of 5‐fluorouracil (5‐FU).3 Pretreated patients underwent
curative resection of primary HCC after diagnosis of disappearance
of pulmonary metastatic foci (patient no. 31), elimination of portal
vein thrombosis (nos 32 and 37), and remarkable shrinkage of the
primary tumor (nos 33, 34, 35, 36, 37) after HAIC therapy. Average
maximum diameter of HCC was 37 mm (range, 10‐110 mm)
(Table 1). Informed consent to participate in the study was obtained
from all patients in accordance with the principles stated in the Dec-
laration of Helsinki and guidelines of the Ethical Committee of Kur-
ume University (study registration no. 15120; Committee Chair,
Kensei Nagata).
2.2 | Chemicals
Dimethyl sulfoxide, SASP, and the antioxidant N‐acetylcysteine
(NAC) were purchased from Sigma‐Aldrich (St Louis, MO, USA).
CDDP was from Wako Pure Chemical Industries, Ltd (Osaka, Japan).
2.3 | Cell lines and culture conditions
Human liver cancer cell lines Huh7 and HepG2 were obtained from
the ATCC (Manassas, VA, USA). HAK‐1A and HAK‐1B were estab-
lished and maintained in our institute.19 HAK‐1A and HAK‐1B cells
are well‐differentiated and poorly differentiated HCC cells, respec-
tively, and the latter are presumed to be derived from HAK‐1A
through clonal dedifferentiation based on p53 mutation analysis.19
HAK‐1B cells are well characterized and commonly used for subcuta-
neous transplantation into nude mice.20 Human colorectal cancer cell
line HCT116 was purchased from RIKEN BioResource Center (Tsu-
kuba, Japan). All cell lines were grown in DMEM (Wako) supple-
mented with 10% heat‐inactivated (56°C, 30 min) FBS (Biowest,
Nuaillé, France), 100 U/mL penicillin, and 100 mg/mL streptomycin
(Nacalai Tesque, Kyoto, Japan) in a humidified atmosphere contain-
ing 5% CO2 at 37°C.
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2.4 | Cell proliferation assay
Cell proliferation was evaluated by counting the viable cells in
suspension prepared with Trypsin‐EDTA solution (Nacalai Tesque)
using a CDA‐500 automated cell counter (Sysmex, Kobe, Japan) at
days 0, 2, 4, and 6 after the treatments with DMSO alone, CDDP
alone, SASP alone, and a combination of CDDP with SASP. To
determine cytotoxicity‐promoting concentration of SASP under
combination treatment with CDDP, HAK‐1B cells (1 × 104 cells/
well in a 6‐well plate) were treated with different concentrations
of CDDP (0, 10, 20, 40, 80, and 100 μM) with or without SASP
at concentrations of 0, 50, and 100 μM for 6 days. Subsequently,
the viable cell number was counted using the CDA‐500 cell
counter.
TABLE 1 Patient characteristics and histological features of HCC
Patient
no. Age Gender LC
Serum
HBsAg
Anti‐HCV
Ab
Size of tumor
(mm)
Histological
pattern
Histological
grading
Prior
treatment
1 71 M − − + 20 × 20 PS WD −
2 69 F − − + 29 × 23 TR WD −
3 62 M − − + 14 × 13 TR WD −
4 72 F + − + 19 × 15 TR WD −
5 76 M + − + 15 × 14 TR >PS WD −
6 69 M − − + 22 × 20 TR >PS WD −
7 73 M + − − 28 × 24 TR WD −
8 74 M + + − 12 × 10 TR >PS WD −
9 69 M + − + 25 × 20 TR >PS WD −
10 75 M − − + 27 × 25 TR >PS WD −
11 73 M + − + 28 × 25 TR MD −
12 71 M + − + 30 × 28 TR MD −
13 81 M − − − 38 × 38 TR >PS MD −
14 64 M − − + 33 × 31 TR MD −
15 75 M + − + 44 × 43 TR MD −
16 70 M − − + 30 × 26 TR >PS MD −
17 56 M + − + 43 × 25 TR MD −
18 58 F + + − 28 × 22 TR MD −
19 75 F − − + 21 × 20 TR >PS MD −
20 81 F − − + 33 × 31 TR MD −
21 77 M + − + 45 × 40 COM MD −
22 75 M + − + 35 × 30 COM >TR PD −
23 63 M − − + 70 × 60 TR PD −
24 77 M − − − 15 × 14 COM >TR PD −
25 54 M − + − 60 × 44 COM PD −
26 53 M + − + 42 × 35 COM >TR PD −
27 78 F − − + 73 × 60 TR >PS PD −
28 74 M − − + 63 × 52 COM >TR PD −
29 58 M − − − 43 × 30 COM PD −
30 80 F + − − 30 × 17 COM >TR PD −
31 72 F − − − 110 × 70 TR MD + PD HAIC
32 77 M − − + 11 × 9 TR MD + PD HAIC
33 84 M + − − 55 × 50 TR >PS MD HAIC
34 75 M − − + 45 × 40 TR MD HAIC
35 62 M − − + 50 × 45 TR >PS MD HAIC
36 84 M − − − 61 × 49 TR >PS MD HAIC
37 73 F − − + 10 × 7 TR MD HAIC
COM, compact; HAIC, hepatic arterial infusion chemoembolization; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C
virus; LC, liver cirrhosis; MD, moderately differentiated; PD, poorly differentiated; PS, pseudoglandular; TR, trabecular; WD, well differentiated; −, none.
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2.5 | Measurement of intracellular ROS
A total of 1 × 104 HAK‐1B cells/well were seeded in a white 96‐well
plate (Thermo Fisher Scientific, Waltham, MA, USA) 2 days before
the analysis. ROS levels were measured using the ROS‐Glo H2O2
Assay kit (Promega Corporation, Madison, WI, USA) according to the
manufacturer's instructions. Briefly, the cells were incubated with
ROS‐Glo Detection Solution for 20 minutes before treatment with
different concentrations of SASP at (0, 50, and 100 μM) and CDDP
(0 and 20 μM) with or without 1 mM NAC for 6 hours. Cell‐derived
ROS in the plates were analyzed using the GLOMAX‐Multi+ Lumi-
nescence System (Promega). ROS levels were determined as values
relative to untreated control. Each assay was carried out in triplicate.
2.6 | Glutathione assay
Intracellular levels of GSH were measured using the GSH‐Glo
Glutathione Assay kit (Promega) according to the manufacturer's
instructions. First, 1 × 104 HAK‐1B cells/well were cultured in a
white 96‐well plate overnight and treated with 20 μM CDDP, with
DMSO vehicle as a control, with or without SASP at concentrations
of 0, 50, and 100 μM for 3 hours. The cells were washed with water
and GSH‐Glo reagent was added to the plate. After incubation, luci-
ferin detection reagent was added and luminescence was measured
using the GLOMAX‐Multi+ Luminescence System (Promega). All
measured GSH concentrations were normalized by the cell number
counted at the time of measurement. Total GSH concentration was
determined from a standard curve prepared using known GSH con-
centrations. All experiments were conducted in triplicate.
2.7 | Sphere formation assay
HAK‐1B‐derived single‐cell suspensions (1.2 × 104 cells/well) were
added to Ultra Low Attachment 6‐well plates (Corning, Inc., Corning,
NY, USA). The cells were treated with SASP alone (0, 50, and
100 μM) and in combination with 50 μM CDDP. After 14 days, the
number of cell aggregates/spheres per well was quantified and pho-
tographed under a KEYENCE BZ‐X700 Fluorescence Microscope
(KEYENCE, Osaka, Japan). The area of the cell aggregates was mea-
sured using MetaMorph 6.0 software (Molecular Devices, Sunnyvale,
CA, USA).
2.8 | Western blotting
Cells were lysed with RIPA buffer (Pierce, Rockford, IL, USA) con-
taining Protease Inhibitor Cocktail (Nacalai Tesque) and Halt Phos-
phatase Inhibitor Cocktail (Pierce). Protein concentrations were
measured using the BCA Protein Assay Kit (Pierce). Samples contain-
ing 25 μg protein were separated on 8% or 10% SDS‐PAGE and
then transferred to equilibrated PVDF membranes (Bio‐Rad, Her-
cules, CA, USA). After blocking with 5% non‐fat milk, the membranes
were incubated with diluted primary antibodies overnight at 4°C.
The primary antibodies for CD44 standard (CD44s) (rabbit
monoclonal), xCT (rabbit monoclonal), cleaved poly (ADP‐ribose)
polymerase (PARP) (rabbit polyclonal), PARP (rabbit polyclonal),
cleaved caspase‐3 (rabbit polyclonal), and caspase‐3 (rabbit poly-
clonal) were purchased from Cell Signaling Technology (Danvers,
MA, USA), and the antibody for CD44 variant 9 (CD44v9) (rat mono-
clonal) was from Cosmo Bio (Tokyo, Japan). Bound antibodies were
detected with HRP‐labeled secondary antibodies using ImmunoStar
LD (Wako). Positive signals from the target proteins were visualized
using an image analyzer (LAS‐4000; Fujifilm, Tokyo, Japan).
2.9 | Immunohistochemistry and staining score
Immunohistochemistry for CD44v9 (rabbit monoclonal; Cosmo Bio)
and xCT (rabbit monoclonal; Cell Signaling Technology) was carried
out using the VECTASTAIN ABC kit (Vector Laboratories, Burlin-
game, CA, USA). Paraffin‐embedded tissue sections were deparaf-
finized and heated in 10 mM sodium citrate buffer (pH 6.0) at
121°C for 5 minutes for antigen retrieval. Sections were preblocked
with normal horse serum from the kit and incubated with the pri-
mary antibodies at 4°C overnight. According to the manufacturer's
protocol, positive signals were visualized by 0.1% 3,3′‐diaminobenzi-
dine‐tetrahydrochloride. Cell nuclei were counterstained with hema-
toxylin. Samples incubated with rat or rabbit IgG were used as
negative controls. Intensity of staining was scored on a scale of 0‐3
as follows: 0, negative staining; 1, mildly positive staining; 2, moder-
ately positive staining; and 3, strongly positive staining. The signal
positive area was scored on a scale of 0‐3 as follows: 0, negative
staining; 1, positive staining in 1%‐10% of cells; 2, positive staining
in 11%‐60% of cells; and 3, positive staining in 61%‐100% of cells.
The scores were summed for each specimen. A total score of ≥1
was considered as positive expression.
2.10 | Xenograft model
HAK‐1B cells (5 × 106 per mouse) were s.c. injected into the backs
of 5‐week‐old male BALB/c athymic nude mice (n = 15) (Clea Japan,
Tokyo, Japan). Tumor size was measured weekly in 2 orthogonal
directions using calipers, and tumor volume (mm3) was estimated
using the equation length × (width)2 × 0.5. We determined the cor-
rect dosages of CDDP and SASP according to the previous report to
maximize their antitumor effects and minimize adverse effects.16
CDDP (1 mg/kg) or DMSO was injected to mice i.p., and SASP sus-
pension (250 mg/kg) was given each day orally by gavage to avoid
i.p.‐related panperitonitis. In this study, the reported dosage of
CDDP (2 mg/kg per injection twice per week for 4 weeks)16 caused
severe renal tubular damage, and therefore we decreased the dosage
to 1 mg/kg per injection 3 times per week for 5 weeks. SASP was
given orally because i.p. dosage of 250 mg/kg per injection twice per
week for 4 weeks16 caused fatal peritonitis. Tumor‐bearing mice
(n = 15) were randomly assigned to 3 groups of 5 mice as follows:
group 1, control i.p. given DMSO 3 times per week (total 15 mg/kg);
group 2, i.p. given CDDP 3 times per week (total 15 mg/kg); and
group 3, i.p. given CDDP 3 times per week (total 15 mg/kg) and
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F IGURE 1 Expression of xCT, CD44s, and CD44v9 in human hepatocellular carcinoma (HCC) tissues. A, xCT is highly expressed in poorly
differentiated HCC tissue (Poor), followed by moderately differentiated (Mod) and well‐differentiated tissues (Well). NT, non‐tumorous tissue.
Scale bars, 100 μm. B, Immunostaining score shows significantly highest expression of xCT in Poor.  P < 0.01; C, Limited number of
CD44v9‐positive HCC cells was observed among several CD44s‐positive cells in Poor. Scale bars, 100 μm. D, CD44v9 was clearly localized to
the cytoplasmic membrane of HCC cells (magnified view of the squared area in C)). Scale bar, 20 μm. E, Immunostaining scores for 30 HCC
tissues studied. CD44v9 was positive in only 2 HCC: untreated with neoadjuvant chemotherapy and presurgical radiation therapy  P < 0.01;
n.s., not significant. F, (left upper panel) H&E staining of HCC tissue after hepatic arterial infusion chemoembolization (HAIC) treatment shows
a viable tumor cell cluster surrounded by necrotic tissue area. Scale bar, 500 μm. (right upper panel) Magnified view of the squared area in the
left upper panel. Scale bar, 50 μm. (left lower panel) CD44v9‐positive HCC cells were observed at the periphery of the tumor pretreated with
neoadjuvant HAIC therapy. Scale bar, 50 μm. (right lower panel) xCT was strongly positive in the same tumor area in the serial section. Scale
bar, 50 μm. Graph shows that CD44v9 positivity was significantly higher in HAIC‐pretreated HCC tissues (71.4%) than in those without
presurgical treatments (10.0%).  P < 0.01
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SASP suspension (250 mg/kg) orally every day. Treatments were
started when the estimated tumor volume reached approximately
30 mm3. The mice were killed at week 5 after the start of treatment
and tumors were resected. Tumor tissues were subjected to H&E
staining and immunohistochemistry. All animal experiments were
conducted in accordance with the NIH Guidelines for the Care and
Use of Laboratory Animals and were approved by the Animal Care
and Use Committee of the University of Kurume.
2.11 | Statistical analysis
All data were expressed as mean ± SD. Kruskal‐Wallis rank test was
carried out to examine the overall significance. If the test result was
significant or showed a trend, Conover‐Iman pairwise test, which
controls the family‐wise error rate to 0.05, was carried out. A mixed‐
effect model was fitted for xenografted tumor volume data. Bonfer-
roni adjustment was used to control multiplicity. Non‐parametric
analyses were carried out using STATA/MP 15.1 (StataCorp LLC,
College Station, TX, USA) and SAS9.4 (SAS Institute Inc., Cary, NC,
USA) was used to fit the mixed models. P < 0.05 was considered
statistically significant.
3 | RESULTS
3.1 | Expression levels of xCT, CD44v9, and CD44s
in human HCC tissues
xCT was diffusely expressed in the cytoplasm of tumor cells in
resected HCC tissues without neoadjuvant chemotherapy, and stain-
ing intensity was significantly stronger in HCC tissues than in histo-
logically normal liver tissues (Figure 1A,B). The positive signal for
xCT was highest in poorly differentiated HCC tissues. CD44s and
CD44v9 expression was observed in the cytoplasmic membrane of
HCC cells (Figure 1C,D), but CD44v9 was expressed in limited areas
of only 2 HCC tissues (patient nos 21 and 27) showing moderate
and poor differentiation, respectively (Figure 1C,D). Immunostaining
scores for 30 HCC tissues studied are shown in Figure 1E. Expres-
sion level of CD44s was highest in poorly differentiated HCC among
the 3 histological grades of HCC, followed by moderately differenti-
ated and well‐differentiated HCC (Figure 1E). In contrast to the low
CD44v9 positivity in resected HCC tissues without neoadjuvant
chemotherapy, expression was observed more often (5/7) in HAIC‐
treated HCC tissues obtained by subsequent surgical resection (Fig-
ure 1F and the related graph) in 5 patients (nos 33‐37). xCT expres-
sion level was also high in those tissues and showed similar levels to
those in primarily resected tissues (Figure 1F).
3.2 | Expressions of CD44v9 and xCT in human
HCC cell lines
Although the expression level of CD44v9 was not so high in the
cells examined, the level was significantly higher in the aggressive
HCC cell line HAK‐1B than in the well‐differentiated counterpart
HAK‐1A cells (Figure 2A). xCT levels were also high in HAK‐1B (Fig-
ure 2A), which is consistent with its expression status in clinical sam-
ples. Because CD44v9 is a marker protein of CSC known to be
condensed in cancer cell spheres/aggregates, we examined whether
CD44v9 expression was increased in spheres/aggregates of HAK‐1A
and HAK‐1B cells. Indeed, the expression was high in sphere‐forming
tumor cells, coupled with increased xCT expression (Figure 2B). This
was also confirmed in other liver cancer cell lines, such as Huh7 and
HepG2 cells (Figure 2C).
3.3 | Synergistic proliferation‐inhibitory effects of
CDDP plus SASP on HCC cells
Because CDDP is a key drug used in chemotherapy for HCC, we
focused on its cytotoxic effect and possible augmentation under
(A) (B) (C)
F IGURE 2 Western blotting for CD44v9 and xCT in human hepatocellular carcinoma (HCC) cell lines. A, HAK‐1B strongly and weakly
expresses xCT and CD44v9, respectively, compared to HAK‐1A, a well‐differentiated HCC cell line. The colon cancer cell line HCT‐116 served
as a positive control for both molecules. B, Cancer cells forming cancer spheres (S) strongly express both CD44v9 and xCT compared to those
under attached conditions (A). C, Condensation of both molecules was universally observed in other liver cancer cell lines, such as Huh7 and
HepG2. Phase contrast images of attached and sphere‐forming cells are shown at the bottom
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combined use with SASP on CD44v9/xCT‐expressing HAK‐1B cells.
HAK‐1A cells, in which CD44v9 expression was low or absent and
xCT expression was low, were highly sensitive to CDDP alone and
thus were not suitable for testing the synergistic cytotoxic effect
(data not shown). As shown in Figure 3A, synergistic inhibition of
cell proliferation was significant at ≥40 μM CDDP in combination
with 100 μM SASP in HAK‐1B cells. This synergistic inhibition was
also observed in sphere‐forming HAK‐1B cells expressing high levels
of CD44v9/xCT (Figure 3B), suggesting that the proliferation of the
CSC‐like cell‐rich population can be decreased by combination treat-
ment with a relatively low dosage of CDDP with SASP, which is rel-
evant to blood concentration.21
3.4 | Sulfasalazine enhanced ROS‐dependent
apoptosis by CDDP
Because SASP was predicted to attenuate the antioxidative potential
of HAK‐1B cells by targeting the xCT system, we measured intracel-
lular ROS and GSH levels in CDDP‐exposed cells with or without
SASP. As expected, intracellular ROS levels were robustly increased
following coincubation with SASP in a dose‐dependent way (Fig-
ure 4A); this increase was clearly abrogated by the antioxidant NAC
(Figure 4A). A sharp but a significant decrease in GSH content was
observed in cells treated with both CDDP and 100 μM of SASP (Fig-
ure 4B), indicating that the drastic increase in ROS production
(A) (B)
F IGURE 3 Inhibition of cell
proliferation by cisplatin (CDDP) plus
sulfasalazine (SASP) in hepatocellular
carcinoma (HCC) cells. A, Synergistic
inhibition of cell proliferation is significant
at ≥40 μM CDDP in combination with
100 μM SASP in HAK‐1B cells
(  P < 0.01). B, A synergistic inhibitory
effect was seen even in sphere‐forming
HAK‐1B cells. As described in Materials
and Methods, imaging analysis of the
number of cell aggregates/spheres per well
was conducted and the cell aggregate area
(%) is shown.  P < 0.01
(A) (B)
(C)
F IGURE 4 Reactive oxygen species
(ROS)‐dependent apoptosis enhanced by
sulfasalazine (SASP). A, SASP significantly
increases intracellular ROS levels in HAK‐
1B cells cotreated with cisplatin (CDDP) in
a dose‐dependent way. N‐Acetylcysteine
(NAC) completely inhibited ROS
production.  P < 0.001. B, Decrease
in intracellular glutathione (GSH) content
was slow but significant in cells exposed to
CDDP and 100 μM SASP.  P < 0.01. C,
In western blotting, the apoptosis markers
cleaved (Cl) poly (ADP‐ribose) polymerase
(PARP) and cleaved caspase (Cas)‐3 were
clearly observed in cells treated with both
CDDP and SASP. When these cotreated
cells were exposed to NAC, apoptosis was
remarkably suppressed (lane 5)
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occurred through GSH exhaustion (Figure 4A). Subsequently, we
examined whether CDDP/SASP‐treated cells were killed through
ROS‐dependent apoptosis by western blotting and confirmed that
caspase‐mediated‐and ROS‐dependent apoptosis was augmented by
concomitant treatment with CDDP and SASP, which was clearly
inhibited by NAC (Figure 4C).
3.5 | Sulfasalazine inhibited xenografted tumor
growth in combination with CDDP
The size of xenografted tumors was decreased by treatments with
CDDP alone and CDDP with SASP (Figure 5A). Tumor size was not sig-
nificantly decreased by treatment with SASP alone at the dosage used
in the present study (Figure S1). At 2 weeks after beginning treatment
with CDDP and SASP, xenografted tumor growth began to be inhibited
compared to that shown in mice treated with CDDP alone (Figure 5B).
After 5 weeks of the combined treatment, tumor growth was signifi-
cantly suppressed compared to that in mice treated with CDDP alone
(Figure 5B). Consistent with the tumor growth inhibition, immunohisto-
chemistry analysis of cleaved caspase‐3 showed the highest significant
positivity in the tumor tissues of mice treated with both CDDP and
SASP (Figure 5C), suggesting that combination treatment induced
robust apoptosis even in vivo. Additionally, combination treatment elim-
inated CD44v9‐positive tumor cells from the xenografted tumors com-
pared to treatment with DMSO (control) and CDDP alone (Figure 5D).
4 | DISCUSSION
The important findings of the present study are as follows: (i)
CD44v9/xCT was robustly expressed in surviving HCC cells in surgi-
cally resected tissues after HAIC therapy; (ii) SASP induced ROS‐
mediated apoptosis in an aggressive HCC cell line expressing high
levels of CD44v9/xCT and suppressed sphere formation in cancer
cells in combination with CDDP; and (iii) combination treatment with
SASP with CDDP had strong growth‐inhibitory effects on xeno-
grafted HCC tumors in athymic mice.
The CSC marker protein CD44v9 is expressed in various types
of cancer, including HCC, gastric cancer, and pancreatic can-
cer.18,22,23 However, CD44v9 expression in HCC pretreated with a
CDDP‐containing chemotherapeutic regimen has not been analyzed
in detail. Notably, we found that the frequency of CD44v9 expres-
sion was significantly increased not only in poorly differentiated
HCC tissues but also in HAIC‐pretreated HCC tissues compared to
in primarily resected tissues without pre‐chemotherapy. This clinico-
pathological finding strongly suggests that CD44v9‐positive cells
exist in poorly differentiated HCC cells and remain alive and prolifer-
ate as resistant cells to chemotherapeutic agents. Consistent with
this finding, both CD44v9 and xCT expression levels were higher in
the poorly differentiated HCC cell line HAK‐1B than in the well‐dif-
ferentiated sister cell line HAK‐1A, which was established from dif-
ferent layers of a single HCC nodule from the same patient.19
Interestingly, the expression level of CD44v9 was enhanced in tumor
cells under sphere formation, where stem cell‐like and CSC‐like cell
populations may be increased.24 These results also suggest that
CD44v9 is a valid CSC marker in the cell lines used in this study.
Patients with advanced HCC showing favorable therapeutic
response to TACE and/or HAIC should be identified before giving sys-
temic treatments, such as sorafenib and regorafenib. One of the key
drugs for TACE and HAIC is CDDP; therefore, we focused on whether
combined use of CDDP with SASP killed HCC cells more efficiently
compared to CDDP alone. Synergistic cytotoxic effects on HCC cells
were seen by the combination of CDDP with SASP, which robustly
increased intracellular levels of ROS and decreased GSH content,
resulting in caspase‐mediated apoptosis. Notably, the apoptotic pro-
cess was inhibited by giving NAC, a strong antioxidant. This suggests
that ROS are critically involved in apoptosis induced by CDDP and
SASP. These findings indicate that SASP can kill CSC‐featured HCC
cells in combination with a key conventional anticancer agent and dis-
rupt redox homeostasis in tumor cells. It is important that such effec-
tive cytotoxicity was observed at concentrations ranging within the
blood concentrations of patients in the ordinary clinical setting.25
The strong growth‐inhibitory effects of combination CDDP with
SASP treatment on xenografted HCC tumors is promising as an alterna-
tive for HCC patients. The effects were based on induction of caspase‐
mediated apoptosis, as observed in our cell culture experiments. How-
ever, potential adverse effects may occur in clinical use. Although SASP
can be safely given to patients with ulcerative colitis and rheumatoid
arthritis,26 it is not commonly used in patients with severe liver injury,
including liver cirrhosis with Child‐Pugh class B and C. Although it is not
legally prohibited to give SASP to patients with inflammatory diseases
complicated by Child‐Pugh class A cirrhosis, its feasibility and safety must
be carefully assessed in patients with advanced HCC in a well‐designed
phase I/II study. According to a recent study of the dose‐escalation of
SASP in patients with gastric cancer, adverse effects in the gastrointesti-
nal tract, including appetite loss, vomiting, and diarrhea, were the main
F IGURE 5 Xenograft experiments in nude mice. A, Representative xenografted tumors (arrows) in nudemice are shown. Black arrows, control
(DMSO); blue, cisplatin (CDDP)‐treated; and red, CDDP/sulfasalazine (SASP)‐treated. B, Size of xenografted tumors was significantly decreased from
weeks 1‐5 by treatment of CDDP alone, compared with that of controls (DMSO) (P < 0.01 at weeks 1, 2, and 3; P < 0.05 at weeks 4 and 5). At week
2 after beginning combinatorial treatment, tumor growth began decreasing compared to that observed in mice treated with CDDP alone. After
4 weeks of dual treatments, tumor growth was significantly suppressed compared to that in mice treated with CDDP alone (  P < 0.001). C,
Consistent with the tumor growth inhibition, immunohistochemistry analysis of cleaved caspase‐3 showed significantly highest positivity in tumor
tissues of mice treated with both CDDP and SASP, suggesting that the drug combination also induces robust apoptosis in vivo (  means P <
0.001 or P < 0.01). D, CD44v9‐positive tumor cells were eliminated from xenografted tumors exposed to both CDDP and SASP (left bottom). Scale
bar, 50 μm. The staining score was calculated as described in Materials andMethods (  P < 0.05;  P < 0.001)
8 | WADA ET AL.
(A)
(B)
(D)
(C)
WADA ET AL. | 9
reasons for discontinuation of the study.17 Therefore, we did not exam-
ine 5‐FU, another key drug in HCC treatment, for combination dosage
with SASP because 5‐FU may frequently induce such gastrointestinal
complications.27 Although several molecular‐targeted drugs, such as len-
vatinib and immune checkpoint inhibitors,28,29 were predicted to be
effective, their efficacy limitations should be examined and novel multi-
disciplinary alternatives for the treatment of HCC should be developed.
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